6th Apr 2021 16:25
Renalytix AI PLC - UK-based diagnostics company - Says KidneyIntelX more accurately predicted progressive kidney function decline and kidney failure in a multi-center, diverse cohort of 1,146 type two diabetes patients with early-stage kidney disease versus the current standard of care. Strong performance of the KidneyIntelX platform is attributed in part to its proprietary, blood-based biomarker technologies.
"Given these additional clinical study findings, we are confident that KidneyIntelX will be adopted as part of the standard of care in assessing the risk of progressive kidney decline in individuals with early-stage diabetic kidney disease," says Michael Donovan, chief medical officer at RenalytixAI.
Current stock price: 920.30 pence, down 0.4% on Tuesday
Year-to-date change: up 89%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc